Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BMEA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Icovamenib (BMF-219) | Type 2 Diabetes Mellitus | Phase 1/2 · NCT05731544 | Completed |
| FLT3 Inhibitor BMF-500 | Acute Myeloid Leukemia | Phase 1 · NCT05918692 | Completed |
| BMF-650 | Obesity | Phase 1 · NCT07223216 | Completed |
| Icovamenib HPMC | Healthy Volunteer | Phase 1 · NCT07254286 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BMEA holds $34.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $10.8M/quarter from operations, an estimated runway of 9.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 52 · Elevated
There is substantial doubt about our ability to continue as a going concern, and we will require substantial additional capital to finance our operations.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BMEA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| CVI Investments, Inc. | 5%+ holder (13G) | 7,847,232 | 10.83% | 2025-12-31 |
| Blue Owl Capital Holdings LP | 5%+ holder (13G) | 4,451,219 | 6.14% | 2025-12-31 |
| JANUS HENDERSON GROUP PLC | Institution (13G, 5%+) | 3,750,000 | 5.17% | 2025-11-28 |
| Bihua Chen Former Director · +202,762 options |
Insider | 3,570,872 | 4.93% | 2025-08-01 |
| Rainer M Erdtmann Officer, Director · +1.84M options |
Insider | 1,847,416 | 2.55% | 2025-12-31 |
| Michael J.M. Hitchcock Interim CEO, Director · +1.98M options |
Insider | 115,000 | 0.16% | 2025-12-02 |
| Franco Valle Chief Financial Officer · +145,245 options |
Insider | 42,995 | 0.06% | 2024-11-30 |
| Juan Pablo Frias Chief Medical Officer · +111,090 options |
Insider | 349 | 0.00% | 2024-05-31 |
Share count 72,483,852 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BMEA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →